Abstract P1-14-02: A phase 2 study of low dose metronomic eribulin in metastatic breast cancer
Chalasani, P, Liu, AJ, Khanjian, JA, Peha, M, Buening, BJ, Gadi, VK, Specht, JM, Salazar, L, Linden, HM
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Get full text
Journal Article
Abstract P4-22-11: Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib
Specht, JM, Gadi, VK, Gralow, JR, Korde, LA, Linden, HM, Salazar, LG, Rodler, ET, Cundy, A, Buening, BJ, Baker, KK, Redman, MW, Kurland, BF, Garrison, MA, Smith, JC, vanHaelst, C, Anderson, JE
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Get full text
Journal Article